---
title: "InterCure Posts Higher 2025 Revenue and EBITDA, Resumes Nir Oz Output and Advances Expansion Plans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276335790.md"
description: "InterCure reported preliminary 2025 results with estimated revenue of NIS 265 million, an 11% year-on-year increase, and positive adjusted EBITDA for the twelfth consecutive half-year. The company resumed operations at its Nir Oz facility, launched over 70 new GMP products, and began generating revenue in Germany. InterCure is advancing its expansion strategy by acquiring Botanico Ltd. and taking a stake in Cannasoul R&D. The latest analyst rating for InterCure stock is a Sell with a price target of ILs283.00."
datetime: "2026-02-19T13:01:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276335790.md)
  - [en](https://longbridge.com/en/news/276335790.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276335790.md)
---

# InterCure Posts Higher 2025 Revenue and EBITDA, Resumes Nir Oz Output and Advances Expansion Plans

### President's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Intercure ( (IL:INCR) ) has provided an update.

On February 19, 2026, InterCure reported preliminary 2025 results showing estimated revenue of NIS 265 million, up about 11% year on year, with nearly 20% growth in the second half and positive adjusted EBITDA for a twelfth consecutive half-year. The company ended 2025 with NIS 43 million in cash, resumed production, imports and sales at its war-damaged Nir Oz facility, launched more than 70 new GMP products, and began generating its first significant German-market revenues.

InterCure also advanced its expansion strategy in 2025 by entering a deal to acquire Botanico Ltd. to bolster access to premium U.S. genetics and cultivation technologies and by taking a 28% stake in Cannasoul R&D to deepen pharmaceutical research capabilities. Management emphasized the firm’s positioning to benefit from evolving cannabis regulations in Europe and the U.S., while pursuing war-damage compensation claims of NIS 251 million and maintaining production continuity amid Bazelet’s restructuring proceedings.

The most recent analyst rating on (IL:INCR) stock is a Sell with a ILs283.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.

**More about Intercure**

InterCure Ltd., operating as Canndoc, is a leading, profitable medical cannabis company based in Israel and listed on Nasdaq and TASE. Through its vertically integrated “seed-to-sale” model, GMP-certified pharmaceutical-grade products, and international partnerships, it targets fast-growing medical cannabis markets outside North America, leveraging a strong domestic footprint and expanding European presence.

**Average Trading Volume:** 104,513

**Technical Sentiment Signal:** Sell

**Current Market Cap:** ILs152.3M

For an in-depth examination of INCR stock, go to TipRanks’ Overview page.

### Related Stocks

- [INCR.US](https://longbridge.com/en/quote/INCR.US.md)

## Related News & Research

- [InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow | INCR Stock News](https://longbridge.com/en/news/284844092.md)
- [Herbal Dispatch Completes Company Record 500kg Medical Cannabis Export Shipment to Europe | LUFFF Stock News](https://longbridge.com/en/news/286883156.md)
- [How Investors May Respond To American Healthcare REIT (AHR) Cutting 2026 Profit Outlook After Q1 Results](https://longbridge.com/en/news/286866277.md)
- [05:54 ETTermHub™ Launches New Managed FHIR Offering for SDOs](https://longbridge.com/en/news/287042225.md)
- [Assessing MillerKnoll (MLKN) Valuation After New EIR Healthcare Partnership In Prefabricated Clinics](https://longbridge.com/en/news/286684089.md)